Mike Montemarano, Associate Editor 03.11.21
An analysis of several large studies involving participants from more than 60 countries, spearheaded by researchers from McMaster University, has found that eating oily fish regularly can help prevent cardiovascular disease (CVD) in high-risk individuals, such as those who already have heart disease or stroke.
The critical ingredient is the omega-3 fatty acids, which researchers found was associated with a lower risk of major CVD events such as heart attacks and strokes by about one sixth in high-risk people who ate two servings of fish rich in omega-3 on a weekly basis.
“There is a significant protective benefit of fish consumption in people with cardiovascular disease,” lead co-author Andrew Mente, associated professor of research methods, evidence, and impact at McMaster and a principal investigator at the Population Health Research Institute (PHRI) of McMaster University and Hamilton Health Sciences, said.
No benefit was observed, however, in participants of the various studies who did not have heart disease or stroke.
“This study has important implications for guidelines on fish intake globally. It indicates that increasing fish consumption and particularly oily fish in vascular patients may produce a modest cardiovascular benefit,” Mente said. He added that people at low risk for CVD can still enjoy modest protection by eating fish rich in omega-3, but the health benefits were less pronounced than those high-risk individuals.
The study was published in JAMA Internal Medicine on March 8.
The findings were based on data sourced from nearly 192,000 people in four studies, including about 52,000 who had CVD, and is the only study of its kind conducted on all five continents. Previous studies focused mainly on North America, Europe, China, and Japan, with little information from other regions.
“This is by far the most diverse study of fish intake and health outcomes in the world and the only one with sufficient numbers with representation from high, middle, and low income countries from all inhabited continents of the world,” study co-lead Dr. Salim Yusuf, professor of medicine at the Michael G. DeGroote School of Medicine and executive director of the PHRI said.
The analysis is based on data from several studies PHRI conducted over the past 25 years. These studies were funded by the Canadian Institutes for Health Research, several different pharmaceutical companies, charities, and the PHRI and Hamilton Health Sciences Research Institute.
The critical ingredient is the omega-3 fatty acids, which researchers found was associated with a lower risk of major CVD events such as heart attacks and strokes by about one sixth in high-risk people who ate two servings of fish rich in omega-3 on a weekly basis.
“There is a significant protective benefit of fish consumption in people with cardiovascular disease,” lead co-author Andrew Mente, associated professor of research methods, evidence, and impact at McMaster and a principal investigator at the Population Health Research Institute (PHRI) of McMaster University and Hamilton Health Sciences, said.
No benefit was observed, however, in participants of the various studies who did not have heart disease or stroke.
“This study has important implications for guidelines on fish intake globally. It indicates that increasing fish consumption and particularly oily fish in vascular patients may produce a modest cardiovascular benefit,” Mente said. He added that people at low risk for CVD can still enjoy modest protection by eating fish rich in omega-3, but the health benefits were less pronounced than those high-risk individuals.
The study was published in JAMA Internal Medicine on March 8.
The findings were based on data sourced from nearly 192,000 people in four studies, including about 52,000 who had CVD, and is the only study of its kind conducted on all five continents. Previous studies focused mainly on North America, Europe, China, and Japan, with little information from other regions.
“This is by far the most diverse study of fish intake and health outcomes in the world and the only one with sufficient numbers with representation from high, middle, and low income countries from all inhabited continents of the world,” study co-lead Dr. Salim Yusuf, professor of medicine at the Michael G. DeGroote School of Medicine and executive director of the PHRI said.
The analysis is based on data from several studies PHRI conducted over the past 25 years. These studies were funded by the Canadian Institutes for Health Research, several different pharmaceutical companies, charities, and the PHRI and Hamilton Health Sciences Research Institute.